Frequent coauthors
- WALLACE OWEN BRENDAN 182
- FRANK Scott Alan 182
- HUMMEL CONRAD WILSON 156
- JONES SCOTT ALAN 156
- Shepherd Timothy Alan 143
- Dally Robert Dean 130
- JONES CHARLES DAVID 104
- LEWIS GEROGE SAL 104
- FAHEY Kennan Joseph 91
- BRYANT HENRY UHLMAN 91
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
Disclosed is an indole sulphonamide compound of formula (I) wherein the substituents are as described in the disclosure. Also disclosed is a pharmaceutical composition comprising a compound of formula (I) and a method for preparing a compou…
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.
The present invention relates to a selective estrogen receptor modulator of formula I or a pharmaceutical acid addition salt thereof; useful, e.g., for treating endometriosis and/or uterine leiomyoma/leiomyomata.